十月 2026
- Home
- Brainomix
十月 2026的Brainomix市场份额分析
Answers to common questions about Brainomix 360 Stroke and e-Lung, covering products, installation, data security, training and support.
Brainomix(包含公司地区分支机构)
查看更多网站流量和参与度信息- brainomix.com
Brainomix收入截至 十月 2026为 2M - 5M
Brainomix主要域名产生的收入
3 年中Brainomix主要域名的收入
Brainomix主要域名的收入
Brainomix热门域名的总访问量
了解Brainomix市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Brainomix热门域名的平均访问时长
分析Brainomix参与度指标。
过去 3 个月的平均访问时长
子公司明细
Brainomix热门域名的平均页面浏览量
了解Brainomix如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Brainomix 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Brainomix partners with Pulmonary Fibrosis Foundation to explore AI-powered pulmonary fibrosis care in England and Illinois on Oct 14th '26OXFORD, England and CHICAGO, Oct. 14, 2026 - Brainomix, a leading medtech company specializing in AI-powered imaging tools for lung disease and stroke, today announced a new partnership with the Pulmonary Fibrosis Foundation (PFF) to bring the voices of patients and caregivers into exploring how AI-powered imaging could support the care of people living with pulmonary fibrosis (PF) and other fibrotic interstitial lung diseases (ILD).
十月 14, 2026阅读更多
新闻Brainomix presents positive results at the European Respiratory Society (ERS) Conference in Spain on Sep 8th '26OXFORD, England and CHICAGO, Sept. 8, 2026 /PRNewswire/ - Brainomix, a leading medtech company specializing in AI-powered imaging tools for lung disease and stroke, and Endeavor BioMedicines, a clinical-stage biotechnology company, presented positive results from the Brainomix AI-driven quantitative analysis of HRCT imaging data in Endeavor's Phase 2a trial of taladegib in idiopathic pulmonary fibrosis (IPF) at the European Respiratory Society (ERS) Conference in Barcelona.
九月 8, 2026阅读更多
查看 Brainomix 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
